CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 2, 2016--
Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome
therapeutics platform company, today announced it will present at the
Cowen and Company 36th Annual Health Care Conference in
Boston on Wednesday, March 9. The presentation will take place in the
Provincetown Room at the Boston Marriott Copley Place at 10 a.m. EST.
Live audio webcast will be available under the Investors and Media
section of Seres’ website. A replay of the presentation will become
available approximately one hour after the event and will be archived
for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. is a leading microbiome therapeutics platform
company developing a novel class of biological drugs that are designed
to treat disease by restoring the function of a dysbiotic microbiome
characterized by an increased presence of pathogenic bacterial species,
where the natural state of bacterial diversity is imbalanced. Seres’
most advanced program, SER-109, has successfully completed a Phase 1b/2
study demonstrating a clinical benefit in patients with recurring Clostridium
difficile infection (CDI) and is currently being evaluated in a
Phase 2 study in recurring CDI. The FDA has granted SER-109 Orphan Drug,
as well as Breakthrough Therapy, designations. Seres’ second clinical
candidate, SER-287, is being evaluated in a Phase 1b study in patients
with mild-to-moderate ulcerative colitis (UC).
View source version on businesswire.com: http://www.businesswire.com/news/home/20160302005202/en/
Source: Seres Therapeutics, Inc.
IR Contact:
Seres Therapeutics
Carlo
Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate
Communications
Ctanzi@serestherapeutics.com
or
PR
Contact:
Ten Bridge Communications
Dan Quinn,
781-475-7974
Dan@tenbridgecommunications.com
